Figure 5.

In vivo efficacy of 50GCG combined with wireless PDT in a mouse orthotopic bladder cancer model. A) Schedule of in vivo efficacy experiment. B) Images of activation of 5 implanted devices with wireless powering at input power 121 mW. C) Kaplan–Meier analysis of disease‐specific survival of the mice in the efficacy experiment. * Log‐rank test for trend significance p < 0.05. D) Weight of harvested bladders after experiment termination. E) Tumor size as indicated by the number of MB49‐PSA cells in each bladder tissue. Free PSA levels in the urine on F) Day 18 and G) Day 25 of the experiment schedule. H) Percentage of mice in each group with small/cured or large tumor sizes. Tumor sizes were defined as small/cured (<20 × 10⁴ cells) or large (>20 × 10⁴ cells) according to the descriptive statistics of control group mice (Table S2, Supporting Information). The experiment was done twice (n = 20). Data were represented as mean ± SD. * p < 0.05, ** p < 0.01, # p < 0.005.